TrialTrials2018

RIVA - a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial.

Sean H Lim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.